EUVIMEDEUVIMED entdecken
Crossref

L26/P-188 Late bloomers or wasted costs? The cost-effectiveness of day7-blastocysts in ICSI–PGT-A cycles

D. Cimadomo, F. Mulas, C.S. Ottolini, M. Cozzolino, F. Innocenti, M. Taggi, A. Reig, A. Vaiarelli, F.M. Ubaldi, A. Capalbo, L. Rienzi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von D. Cimadomo und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Is it cost-effective to include day7-blastocysts in ICSI cycles with PGT-A? Summary answer A routine use of day7-blastocysts is not cost-effective. Conversely, it is cost-effective in women 35-41yr and/or when <3 sibling day5/6-blastocysts are obtained. What is known already Clinical use of day7-blastocysts remains controversial. Laboratory practices differ widely depending on previous experience with these embryos, staff training, and national regulations. While some centers routinely deselect day7-blastocysts, robust data from laboratories that systematically culture and use them show that these embryos can be competent, especially if they display good morphological quality. Their use may significantly increase the chance of achieving a live-birth, particularly in patients with poor-prognosis and limited embryo availability. However, the literature still lacks solid evidence on the cost-effectiveness of their clinical use, especially when compared with performing a second IVF attempt. Study design, size, duration Model-based cost-effectiveness analysis (CEA) developed from 6830 first oocyte-retrievals planned for ICSI–PGT-A (2015–2022). A decision-tree model simulated two IVF pathways over ≤2 attempts among patients obtaining ≥1 day7 (17%): day7-exclusion versus day7-inclusion (biopsy, vitrification plus euploid-transfer). Individuals not achieving a live-birth were assigned specific probabilities of pursuing a second cycle, transitioning to egg-donation, and discontinuing treatment based on historical data. The possible use of day7-blastocysts was incorporated also in the second-cycle branch. Participants/materials, setting, methods Observed day5/6/7-specific live-birth-rates (LBR) per euploid-transfer and costs were used in the model. Incremental-costs and LBR were combined to estimate incremental-cost-effectiveness-ratios (ICER). A willingness-to-pay (WTP) threshold of €422.25 per 1%-increase in LBR was derived from a survey administered to our patients. Sub-analyses were run per maternal age ranges and number of sibling day5/6-blastocysts obtained. Main results and the role of chance Observed LBR per euploid-transfer were 58%, 43% and 18% for day-5,-6 and -7 blastocysts. After a failure 50% of patients discontinued the treatment (ranging 35% to 60% based on maternal age), 40% pursued a second attempt (ranging 65% to 20%) and 10% transitioned to egg-donation (ranging 0% to 20%). These probabilities were used to build a decisional tree. Overall, including day7-blastocysts involved a 4.1% absolute-increase in cumulative-LBR at first attempts, and 1.9% at the end of the treatment for an ICER per 1%-increase of 456€, 33.75€-higher than the WTP threshold. The sub-analyses per maternal age outlined that using day7-blastocysts was cost-effective in the range 35-41yr (cLBR absolute increase:3.7%-7.1% at first attempt and 1.9%-5.5% at the end of the treatment; ICER per 1%-increase:140€-444€). The sub-analysis per number of embryos in the first cohort outlined that using day7 was cost-effective with 0 (cLBR absolute increase:6.3% at first attempt and 5.5% at the end of the treatment; ICER per 1%-increase:242€) or 1-2 sibling day5/6-blastocysts (cLBR absolute increase:4.2% at first attempt and 3.2% at the end of the treatment; ICER per 1%-increase:285€). Limitations, reasons for caution The model’s assumptions were based on data and costs of one Italian private clinic. In Italy, Law 40/2004 prevents discarding viable embryos, including day7. Embryo morphology, although subjective, represents a confounder, especially as day7-blastocysts are often ≤BB. The survey to outline WTP thresholds among specific patients’ populations requires more responses. Wider implications of the findings Whenever allowed by Law, a personalized, rather than routine, clinical use of day7-blastocysts is advisable. Their inclusion may represent a cost-effective strategy in specific patient subgroups potentially reducing the need for additional IVF cycles while optimizing cLBR outcomes, particularly in older women and/or those with <3 sibling day5/6-blastocysts. Trial registration number No

Zitieren

APA

Cimadomo, D., Mulas, F., Ottolini, C., Cozzolino, M., Innocenti, F., Taggi, M., Reig, A., Vaiarelli, A., Ubaldi, F., Capalbo, A., & Rienzi, L. (2026). L26/P-188 Late bloomers or wasted costs? The cost-effectiveness of day7-blastocysts in ICSI–PGT-A cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.524

Vancouver

Cimadomo D, Mulas F, Ottolini C, Cozzolino M, Innocenti F, Taggi M, et al. L26/P-188 Late bloomers or wasted costs? The cost-effectiveness of day7-blastocysts in ICSI–PGT-A cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.524

BibTeX
@article{Cimadomo2026,
  author = {Cimadomo, D. and Mulas, F. and Ottolini, C.S. and Cozzolino, M. and Innocenti, F. and Taggi, M. and Reig, A. and Vaiarelli, A. and Ubaldi, F.M. and Capalbo, A. and Rienzi, L.},
  title = {L26/P-188 Late bloomers or wasted costs? The cost-effectiveness of day7-blastocysts in ICSI–PGT-A cycles},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.524}
}
Kostenlos starten →